

Performance in Initiating HRA Approved Studies - Q2 2020/21

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Source for delay correspond to:
19/LO/0553	257627	GALACTIC-1 - A randomized, double-blind, multicentre, parallel, placebo controlled	22/10/2018	11/11/2019	24/09/2019	20/04/2020	21/04/2020			
19/LO/1317	268821	A Phase 3 study of the long-term safety and efficacy of a triple combination th	16/05/2019	21/01/2020	29/10/2019	05/03/2020	18/03/2020	19/03/2020	07/04/2020	
19/EE/0242	257616	Measurement of mucus plugging with computer tomography before and follo	14/11/2019	14/11/2019		11/02/2020	11/02/2020	11/02/2020	04/03/2020	
19/NW/0716	273613	A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor	04/10/2019	14/10/2019	17/01/2020	22/04/2020	22/04/2020	31/05/2020	07/05/2020	
19/EE/0043	251991	The Residual inflammation imaging to Predict cardiovascular disease progres	05/11/2019	20/03/2020		12/03/2020	03/09/2020	07/09/2020	23/09/2020	
19/NE/0110	257719	A randomised, double-blind, placebo-controlled, cross-over trial of zibotentan	28/05/2019	30/06/2020	04/12/2019					
20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	16/03/2020	16/03/2020	17/03/2020	25/03/2020	25/03/2020	25/03/2020	25/03/2020	
18/LO/0660	237150	Randomized, Embedded, Multifactorial, Adaptive Platform trial for Communit	08/04/2020	23/04/2020	23/07/2018	05/06/2020	08/06/2020	09/06/2020		
20/EE/0135	282213	Multiarm Therapeutic study in pre-ICU patients admitted with COVID-19 - Rep	05/05/2020	18/05/2020	06/05/2020	22/06/2020	22/06/2020	22/06/2020		
20/SC/0179	281904	A phase 2/3 study to determine the efficacy, safety and immunogenicity of the	11/05/2020	13/05/2020	04/05/2020	28/05/2020	28/05/2020			